Could a vaccine stop Triple-Negative breast cancer from coming back?
NCT ID NCT04674306
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This early-phase trial tests an experimental vaccine made from the alpha-lactalbumin protein, found in breast tissue, to see if it can safely train the immune system to fight triple-negative breast cancer cells. The study enrolls people who have completed treatment for non-metastatic triple-negative breast cancer but remain at high risk of recurrence. Researchers are testing different doses to find the safest and most effective one.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental vaccine made from the alpha-lactalbumin protein, combined with an immune-boosting adjuvant called zymosan
- What this could lead to
- If successful, this vaccine could train the immune system to recognize and destroy leftover breast cancer cells, potentially preventing the cancer from coming back.
- What could go wrong
- This is a very early (Phase 1) trial with only 35 participants, so the main goal is safety and dosing—not yet proof that the vaccine works. It may not trigger a strong enough immune response or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIA-IIIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, 44915, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers
- New combo attack on aggressive breast cancer brain tumors shows promise in early trial
- New cocktail of drugs hopes to tackle tough breast cancer